cas 57260-71-6|| where to buy N-Boc-piperazine

Product Name:N-Boc-piperazine

IUPAC Name:tert-butyl piperazine-1-carboxylate

Packing Unit	Available Stock	Price($)
CM103943-500g	in stock	ƚĳ
CM103943-1000g	in stock	řƴƴ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 57260-71-6 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:57260-71-6; Molecular Formula:C9H18N2O2; Melting Point:-; Smiles Code:CC(C)(C)OC(=O)N1CCNCC1; Density:

: Catalog Number:CM103943; Molecular Weight:186.26; Boiling Point:; MDL No:MFCD00075265; Storage:

: PROTAC-Linkers; PROTACs (Proteolytic Targeting Chimeric Molecules) are heterobifunctional protein degraders and are promising targeted therapy candidates for cancer. PROTAC is composed of three parts, one end is connected with the ligand bound by E3 ligase, the other end is connected with the ligand bound by the target protein, and the middle is the linker.; Protac Linkers; where to buy PROTAC-Linkers, Chemenu is research-based manufacturer of pharmaceutical intermediates. We supply Protac Linkers with low price.Warmly welcome new and old customers to visit!

: Piperazines; Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

: Avapritinib; Blueprint Medicines announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe.  AYVAKYT was designed to potently and selectively target KIT D816V, the primary underlying driver of the disease.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

: Saruparib; Saruparib, a selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), demonstrated a promising objective response rate and progression-free survival in patients with certain homologous recombination repair (HRR)-deficient breast cancers, according to results from the phase I/II PETRA trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2024.
Saruparib, a PARP1-specific inhibitor, showed promising tumor growth inhibition in preclinical models of breast, ovarian, pancreatic, and prostate cancer harboring HRR deficiency mutations. Because saruparib was less toxic than other PARP inhibitors, it could be given at higher doses.